Vera Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
VERA
- Investments
-
2
- Share Price
-
$47.70
- (As of Tuesday Closing)
Vera Therapeutics General Information
Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact Information
Website
www.veratx.comCorporate Office
- 8000 Marina Boulevard
- Suite 120
- Brisbane, CA 94005
- United States
Corporate Office
- 8000 Marina Boulevard
- Suite 120
- Brisbane, CA 94005
- United States
Vera Therapeutics Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$47.70 | $45.17 | $9.99 - $50.78 | $2.96B | 62M | 672K | -$2.20 |
Vera Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,628,686 | 552,962 | 434,811 | 482,347 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (115,439) | (100,182) | (89,813) | (32,427) |
Net Income | (107,850) | (95,990) | (89,056) | (32,609) |
Total Assets | 397,291 | 175,546 | 131,435 | 83,748 |
Total Debt | 52,834 | 53,708 | 31,286 | 4,923 |
Vera Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Vera Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Vera Therapeutics Comparisons
Industry
Financing
Details
Vera Therapeutics Competitors (63)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
TG Therapeutics | Corporation | Morrisville, NC | ||||
Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
Polaris Group (California) | Formerly PE-Backed | Grand Cayman, Cayman Islands | ||||
Sutro Biopharma | Formerly VC-backed | South San Francisco, CA |
Vera Therapeutics Patents
Vera Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2021288699-A1 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | ||
EP-4165078-A1 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | ||
CA-3186736-A1 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | ||
US-20230220051-A1 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | ||
EP-4165078-A4 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | C07K16/084 |
Vera Therapeutics Signals
Vera Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Vera Therapeutics Investments & Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) | 17-Dec-2021 | Drug Discovery | |||
PNA Innovations | 26-Apr-2021 | Merger/Acquisition | Biotechnology |
Vera Therapeutics ESG
Risk Overview
Risk Rating
Updated October, 26, 2023
26.52 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Vera Therapeutics FAQs
-
When was Vera Therapeutics founded?
Vera Therapeutics was founded in 2016.
-
Where is Vera Therapeutics headquartered?
Vera Therapeutics is headquartered in Brisbane, CA.
-
What is the size of Vera Therapeutics?
Vera Therapeutics has 72 total employees.
-
What industry is Vera Therapeutics in?
Vera Therapeutics’s primary industry is Drug Discovery.
-
Is Vera Therapeutics a private or public company?
Vera Therapeutics is a Public company.
-
What is Vera Therapeutics’s stock symbol?
The ticker symbol for Vera Therapeutics is VERA.
-
What is the current stock price of Vera Therapeutics?
As of 05-Nov-2024 the stock price of Vera Therapeutics is $47.70.
-
What is the current market cap of Vera Therapeutics?
The current market capitalization of Vera Therapeutics is $2.96B.
-
Who are Vera Therapeutics’s competitors?
TG Therapeutics, Aldeyra Therapeutics, Apellis Pharmaceuticals, Polaris Group (California), and Sutro Biopharma are some of the 63 competitors of Vera Therapeutics.
-
What is Vera Therapeutics’s annual earnings per share (EPS)?
Vera Therapeutics’s EPS for 12 months was -$2.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »